Recruiting
Minocycline in Stroke Study at Maimonides
NCT07237048· Phase 2/3· Source
Enrolling by invitation
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
NCT07116668· Source
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT06952660· Phase 4· Source
Enrolling by invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
NCT06823115· Source
Recruiting
Nebulized Ketamine for the Treatment of Major Depressive Disorder
NCT06752759· Phase 3· Source
Recruiting
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
NCT06410209· Phase 2· Source
Recruiting
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
NCT06473597· Phase 4· Source
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464· Phase 3· Source
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· Source
Active, not recruiting
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
NCT06144645· Phase 3· Source
Active, not recruiting
Impact of Bright Light Therapy on Prader-Willi Syndrome
NCT05939453· Source
Active, not recruiting
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· Phase 3· Source
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Source
Active, not recruiting
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· Phase 3· Source
Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· Phase 1/2· Source
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· Phase 3· Source
Active, not recruiting
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· Phase 3· Source
Recruiting
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368· Phase 2· Source
Enrolling by invitation
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT05368038· Source
Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· Phase 2· Source
Active, not recruiting
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
NCT04089358· Phase 3· Source
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· Phase 3· Source
Recruiting
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· Phase 3· Source
Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· Phase 3· Source
Active, not recruiting
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· Phase 3· Source
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382· Phase 2· Source
Active, not recruiting
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03595124· Phase 2· Source
Recruiting
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03126916· Phase 3· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384· Phase 3· Source
Active, not recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· Phase 3· Source
Active, not recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· Phase 3· Source
Active, not recruiting
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628· Phase 2· Source
Recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· Phase 3· Source
Active, not recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· Phase 3· Source
Active, not recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· Phase 3· Source
Active, not recruiting
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
NCT02466971· Phase 3· Source
Recruiting
Project: Every Child for Younger Patients With Cancer
NCT02402244· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· Source
Active, not recruiting
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967· Phase 3· Source
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· Source
Recruiting
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436· Source
Active, not recruiting
Communication Skills Intervention to Promote Transition Into Survivorship
NCT01483664· Source
Active, not recruiting
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· Phase 2· Source
Active, not recruiting
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007· Phase 3· Source
Active, not recruiting
PRE-DETERMINE Cohort Study
NCT01114269· Source